Amiodarone Maintenance Dosing for Atrial Fibrillation

Guideline-Recommended Dosing

The American College of Cardiology, American Heart Association, and European Society of Cardiology guidelines recommend amiodarone maintenance dosing for atrial fibrillation as 100 to 400 mg daily 1
The American College of Cardiology guidelines specify maintenance dosing of 200 mg daily after appropriate loading, with notation that lower doses may be effective 2

Low-dose amiodarone may be effective and associated with fewer side effects than higher-dose regimens, according to the American College of Cardiology and European Heart Journal 1, 3, 4
The American Family Physician guidelines emphasize keeping amiodarone dosage at the lowest effective level to minimize toxicity 5, 6

The American College of Cardiology recommends 100 mg daily as a maintenance therapy after successful rhythm control with higher loading doses 1
The American Family Physician guidelines suggest using 100 mg daily in elderly patients or those at higher risk for toxicity 5

The American College of Cardiology recommends a loading dose of 600 mg per day for one month or 1000 mg per day for one week before transitioning to maintenance 1
An alternative loading strategy is 800 mg daily for 1 week, then 600 mg daily for 1 week, then 400 mg daily for 4-6 weeks, before reducing to 200 mg maintenance, according to the American College of Cardiology 2

The American Family Physician guidelines recommend liver and thyroid function tests at least every 6 months 5, 6
The American College of Cardiology recommends ophthalmologic examination for corneal deposits and ECG monitoring for QT prolongation and bradycardia 1, 5

Amiodarone is more effective than Class I agents and sotalol for maintaining sinus rhythm, according to the American College of Cardiology and European Heart Journal 1, 3

The American College of Cardiology recommends amiodarone (including 100 mg maintenance) for patients with left ventricular hypertrophy, heart failure, coronary artery disease, or previous MI (low proarrhythmic risk) 1
Amiodarone is also recommended for refractory AF after failure of other antiarrhythmic drugs, according to the American College of Cardiology and European Heart Journal 1, 3

The American College of Cardiology recommends amiodarone as a second-line agent for maintaining sinus rhythm in atrial fibrillation, due to significant extracardiac toxicity, except in patients with structural heart disease where it is the preferred first-line choice, with low proarrhythmic risk 7

Patients with structural heart disease, such as left ventricular hypertrophy, heart failure, coronary artery disease, or prior MI, should be considered for first-line use of amiodarone, as it carries low proarrhythmic risk in these populations 7
The American College of Cardiology suggests that amiodarone provides effective rate control, often eliminating the need for separate rate-control medications, in patients with structural heart disease 7

Amiodarone is more effective than Class I agents in maintaining sinus rhythm, with 62% of patients maintaining sinus rhythm at 1 year, compared to 23% with Class I agents 7
Amiodarone is more effective than sotalol in maintaining sinus rhythm, with 60% of patients maintaining sinus rhythm, compared to 38% with sotalol 7
The American College of Cardiology reports that amiodarone increases the success rate of electrical cardioversion and prevents early relapses by suppressing atrial ectopy 7, 8

The American College of Cardiology recommends a standard loading regimen of 600 mg/day for 1 month or 1000 mg/day for 1 week, followed by a maintenance dose of 200 mg daily, although a low-dose option of 100-200 mg daily may be equally effective with fewer side effects 7, 8

Amiodarone increases the success rate of electrical cardioversion, with 83% of patients remaining in sinus rhythm at 6 months, compared to 43% with quinidine 7, 8
The American College of Cardiology suggests that amiodarone reverses atrial remodeling and inhibits AF inducibility, leading to improved outcomes 7, 8